摘要
抗生素是治疗细菌性传染病的特效药,但抗生素的滥用导致细菌产生耐药性从而使已有抗生素逐渐失效。因此研究新的抗菌策略,寻求新型抗菌药物迫在眉睫。目前主要的抗菌策略有两种,一种是"直接抗菌",另一种是"间接抗菌"。本文重点关注"间接抗菌策略",即挖掘能增加已有抗生素抗菌能力的化合物,称之为抗菌增敏剂。抗菌增敏剂本身不具有抗菌活性,但它能通过逆转细菌的耐药机制、抑制抗生素灭活酶的活性、增强宿主的防御机制等手段来恢复或增强已有抗生素的抗菌活性。本文综述了抗菌增敏剂逆转细菌耐药的作用机理以及结核分枝杆菌抗菌増敏剂的研究进展,以期为开发新的抗结核药物提供思路。
Antibiotics are specific medicine for the treatment of bacterial infections, but the abuse of antibiotics causes the bacteria to develop resistance and gradually invalidate antibiotics. Therefore, it is urgent to develop new antibacterial strategies. At present, there are two main antibacterial strategies. One is ＂direct antibacterial＂ and the other one is ＂indirect antibacterial＂. This article focuses on ＂indirect antibacterial strategy＂ which is excavating compounds that increase the antibacterial ability of antibiotics, so called sensitizers. The sensitizers do not have antibacterial activity, but they can restore or enhance the antibacterial activity of antibiotics by reversing the resistance mechanism of bacteria, such as inhibiting the activity of antibiotic inactivating enzymes and enhancing the defense mechanism of the host. This paper summarized the mechanism of sensitizers to reverse bacterial resistance and focused on antimycobacterial sensitizers, in order to provide ideas for the development of new anti-tuberculosis strategies.
作者
艾雪峰
敬帅
李武
Ai Xue-feng;Jing Shuai;Li Wu(College of Life Sciences,Neijiang Normal University,Neijiang,641100;Key Laboratory of Regional Characteristic Agricultural Resources,Neijiang,641100)
出处
《国外医药（抗生素分册）》
CAS
2018年第6期488-493,共6页
World Notes on Antibiotics
基金
四川省教育厅项目(16ZB0299)
大学生科研立项(16NSD-51
17NSD-142)
大学生创新创业训练计划项目(X2017013)
关键词
结核分枝杆菌
抗菌增敏剂
耐药
Mycobacterium tuberculosis
sensitizers
antibiotic resistance
